The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

In its first full quarter, Attruby made more headway than analysts anticipated in its competition with Pfizer’s ...

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

Deals with Hims & Hers, LifeMD and Ro follow dismissal of a lawsuit that challenged the FDA's determination Wegovy is no ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

The delay for Stealth Biotherapeutics comes amid a heightened focus on the impact FDA job cuts might have on drug reviews.

Trium Capital is the latest firm to push a biotech “zombie” to shut down, claiming in a regulatory filing there is more ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...